Trade AVIR stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Atea Pharmaceuticals, Inc. (AVIR) is trading at US$5.33, up 1.33% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$435.51M. Over the past 52 weeks, AVIR has traded between US$2.78 and US$6.45. On Syfe you can trade AVIR with $0 commission and add it to your watchlist.
| Previous close | US$5.26 |
|---|---|
| Market cap | US$435.51M |
| 52-week range | US$2.78 – US$6.45 |
| Volume | 600.44K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Year: 2020
--Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating
Aug 13, 9:35 AM · MT Newswires
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
Jul 28, 12:27 PM · MT Newswires
Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment
Jul 14, 11:28 AM · MT Newswires
Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America
Jun 25, 11:54 AM · MT Newswires
Atea Pharmaceuticals, Inc. (AVIR) stock is trading at US$5.33, +1.33% from the previous close of US$5.26.
The market cap for Atea Pharmaceuticals, Inc. (AVIR) stock is approximately US$435.51M.
The 52-week high for Atea Pharmaceuticals, Inc. (AVIR) stock is US$6.45.
The 52-week low for Atea Pharmaceuticals, Inc. (AVIR) stock is US$2.78.
Atea Pharmaceuticals, Inc. (AVIR) does not currently pay a dividend.
Stay on top of AVIR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
